Major bleeding · adults with arrhythmias undergoing catheter ablation
Interrupted showed no clear difference in major bleeding compared with uninterrupted anticoagulation therapy (low certainty).
1 finding from 1 review
Composite endpoint of thromboembolic events (stroke or systemic embolism), major bleeding events, and all‐cause mortality · adults with arrhythmias undergoing catheter ablation
Interrupted may leads to lower composite endpoint of thromboembolic events (stroke or systemic… compared with uninterrupted anticoagulation therapy (low certainty).
1 finding from 1 review
Minor bleeding · adults with arrhythmias undergoing catheter ablation
It is very uncertain whether interrupted changes minor bleeding compared with uninterrupted anticoagulation therapy (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with arrhythmias undergoing catheter ablation
Interrupted showed no clear difference in all‐cause mortality compared with uninterrupted anticoagulation therapy (low certainty).
1 finding from 1 review
Asymptomatic thromboembolic events · adults with arrhythmias undergoing catheter ablation
It is very uncertain whether interrupted changes asymptomatic thromboembolic events compared with uninterrupted anticoagulation therapy (very low certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in symptomatic VTE compared with placebo (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).
1 finding from 1 review
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).
3 findings from 1 review
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.
3 findings from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.
3 findings from 1 review
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in symptomatic PE compared with placebo (low certainty).
1 finding from 1 review